FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of prematurity diseases, namely to the use of a combination of pulmonary surfactant alpha. Use of a combination of pulmonary surfactant alpha, delivered in dose of 200 mg/kg of body weight, with budesonide, delivered in dose of 0.1 mg/kg of body weight, for prevention of bronchopulmonary dysplasia (BPD) in premature newborns.
EFFECT: use of the group of inventions provides a reduction in the dose of budesonide in the practant while maintaining efficacy for improving the physiology and inflammation values with lower systemic effects, higher safety while maintaining efficacy as a drug for preventing BPD in premature newborns, as well as increasing volume at 40 cm H2O and reducing the average airway pressure.
9 cl, 4 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMBINATION FOR THE TREATMENT OF DEVELOPING BPD CONTAINING PULMONARY SURFACTANT AND STEROID | 2017 |
|
RU2757902C2 |
| THERAPEUTIC COMBINATION CONTAINING LUNG SURFACTANT AND STEROID | 2010 |
|
RU2533450C2 |
| THERAPEUTIC COMBINATION CONTAINING LUNG SURFACTANT AND ANTIOXIDANT ENZYMES | 2010 |
|
RU2538675C2 |
| METHOD OF COMPLEX DRUG PREVENTION OF BRONCHOPULMONARY DYSPLASIA IN PRETERM NEWBORN BABIES | 2010 |
|
RU2432953C1 |
| METHOD FOR PREDICTION OF BRONCHOPULMONARY DYSPLASIA IN NEWBORNS WITH VERY LOW OR EXTREMELY LOW BIRTH BODY WEIGHT | 2012 |
|
RU2504395C1 |
| METHOD OF PREVENTING BRONCHOPULMONARY DYSPLASIA IN NEWBORN BABIES WITH VERY LOW AND EXTREMELY LOW BODY WEIGHT AT BIRTH | 2009 |
|
RU2416388C1 |
| METHOD OF PREDICTING BRONCHOPULMONARY DISPLASIA IN CHILDREN WITH INHERENT PNEUMONIA | 2010 |
|
RU2439569C1 |
| RECONSTITUTED PULMONARY SURFACTANTS | 2013 |
|
RU2656185C2 |
| METHOD OF PREDICTING BRONCHOPULMONARY DYSPLASIA DEVELOPMENT IN PREMATURE INFANTS WITH EXTREME LOW BODY WEIGHT AT BIRTH | 2012 |
|
RU2514013C2 |
| METHOD AND SYSTEM FOR ADMINISTRATION OF PULMONARY SURFACTANT BY ATOMISATION | 2014 |
|
RU2671205C2 |
